IRF4

(redirected from MUM1)

IRF4

A gene on chromosome 6p25-p23 that encodes a member of the interferon regulatory transcription factor (IRF) family, which is characterised by an unique tryptophan pentad-repeat DNA-binding domain. IRF4 is lymphocyte specific and negatively regulates Toll-like-receptor (TLR)-signalling, which is central to activating the innate and adaptive immune systems.

Molecular pathology
A chromosomal translocation involving IRF4 and the IgH locus, t(6;14)(p25;q32), has been linked to myeloma.
Mentioned in ?
References in periodicals archive ?
Immunochemistry showed CD45, BCL-2, BCL-6, CD10, CD20, and CD79a positivity and CD30, MUM1, EBER, and CD34 negativity.
Along with the diagnosis, there is an increasing need to evaluate prognostic markers like CD10, BCL2, BCL6 and MUM1 to subcategorize DLBCL into Germinal Centre (GC) type or Activated B Cell (ABC) type as they have different survival rates.
In addition, there is greater variability in the nuclear size and morphology, and most cases of BL in the HIV setting express MUM1.
The expression of BCL6, MUM1 and CD138 in these lymphomas corresponds to the stage from which they are thought to develop [13,14].
patients express cytoplasmic immunoglobulin, CD38, CD138, and IRF4/ MUM1 and are usually negative or only weakly positive for CD45, CD20, and PAX5.
Plasmablastic lymphoma characteristically shows immunophenotypic evidence of terminal B-cell differentiation with expression of CD38, CD138, and MUM1.
They are also frequently positive for MUM1 (75%), BCL6 (46%), BCL2 (78%), and CD23 (70%).
As mentioned earlier, MUM1 protein expression is common in C-ALCL and ALK+ and ALK- ALCL, making the biologic significance of IRF4 translocation uncertain at the present time.
The antibodies were specific for CD5 (Labvision/Neomarker, Montreal, Quebec, Canada), CD10 (Novocastra/Vision Biosystem, Benton Lane, Newcastle upon Tyne, United Kingdom), CD20 (Dako, Carpinteria, California), CD30 (Dako), CD138 (Serotec, Raleigh, North Carolina), PAX5 (Transduction Labs, San Diego, California), BCL2 (Novocastra/Vision Biosystem), BCL6 (Dako), MUM1 (Santa Cruz Biotechnology, Santa Cruz, California), ALK (Dako), MIB-1 (Ki-67, Dako), p53 (Dako), and p63 (clone 4A4, Santa Cruz Biotechnology).
13) Sections were incubated at room temperature for 30 minutes with the following antibody panel: CD3, CD20, BCL-2, CD30, CD43, CD10, CD5, CD23, CD27, BCL-6, CD38, PAX5, MUM1, latent membrane protein (LMP-1), AID, and [kappa] and [lambda] light chains (Table 1).
Primary bone lymphoma can be further divided into germinal-center B-cell type and non-germinal-center B-cell type by using CD10, BCL6, and MUM1 antibodies (Figure 1, B through D).